Company Overview - Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on creating new medicines for pain and fatigue-related disorders [3] - The company is publicly traded on Nasdaq under the ticker DWTX [3] Upcoming Events - Dogwood Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025 [1] - CEO Greg Duncan will engage in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright on September 5, 2025, with the presentation available on-demand [2] Research and Development - The company has a research pipeline that includes a non-opioid analgesic program and an antiviral program [3] - The lead candidate in the analgesic program is Halneuron, which targets voltage-gated sodium channels to reduce pain transmission, showing efficacy in treating cancer-related pain and chronic chemotherapy-induced neuropathic pain [3] - Interim data from the ongoing Phase 2 study of Halneuron for chronic chemotherapy-induced neuropathic pain is expected in Q4 2025 [3] Antiviral Program - Dogwood's antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib [4] - IMC-1 is advancing towards Phase 3 development for fibromyalgia, while IMC-2 has shown success in reducing fatigue associated with Long-COVID in clinical trials [4] - The company has reached an agreement with the FDA to use fatigue reduction as the primary endpoint for future IMC-2 research related to Long-COVID [4]

Core Insights - Adagene Inc. has appointed Dr. Axel Hoos as Executive Advisor, enhancing its leadership in immuno-oncology [1][2] - The company is advancing innovative antibody therapies targeting CTLA-4, aiming to improve efficacy and reduce toxicity in cancer treatment [2][6] - Dr. Hoos brings extensive experience in immuno-oncology, having previously led the development of YERVOY, the first FDA-approved immune checkpoint inhibitor [2][3][4] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [5] - The company utilizes its SAFEbody precision masking technology to address safety and tolerability challenges in antibody therapeutics [6] Pipeline and Technology - Adagene's lead clinical program, ADG126, is a masked anti-CTLA-4 SAFEbody currently in phase 1b/2 studies, particularly targeting Metastatic Microsatellite-stable Colorectal Cancer [7] - The SAFEbody platform allows for tumor-specific targeting while minimizing off-tumor toxicity, enhancing the therapeutic window for antibody treatments [6][7]

Editas Medicine (EDIT) FY 2025 Conference September 03, 2025 08:00 AM ET Company ParticipantsDana Sheehan - Associate Director - Corporate CommunicationsGilmore O’Neill - Director, President & CEOLinda Burkly - EVP & Chief Scientific OfficerAlec Stranahan - VP - Equity ResearchBill Maughan - MD, Equity Research - BiotechnologyJonathan Miller - MD - Biotech & Pharma Equity ResearchSoumit Roy - MD - HealthcareTony Deng - VP - Biotechnology Equity ResearchConference Call ParticipantsJack Allen - Senior Researc ...

Editas Medicine (EDIT) FY 2025 Conference September 03, 2025 08:00 AM ET Speaker0Our lead development candidate, Edit 401. This webinar is being recorded and can be accessed in the future through this same link or through the Investors section of the company's website. After our prepared remarks, we will open the call to Q&A. To ask a question, please click the raise hand feature in the webinar portal. As a reminder, various remarks that we make during this presentation about the company's future expectatio ...

AnaptysBio (ANAB) 2025 Conference September 03, 2025 08:00 AM ET Company ParticipantsPrakhar Agrawal - Managing DirectorDaniel Faga - President & CEOPrakhar AgrawalAll right. Hello, everyone. Good morning. Welcome to day one of the CANTER Global Healthcare Conference. For the first session today, we have AnaptysBio. My name is Prakhara Gurwal. I'm a biotech analyst on CANTER. Joining us from AnaptysBio, we have Dan Faga, President and Chief Executive Officer. Dan, thank you for coming to us.Daniel FagaGood ...

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight TimeH.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a. ...

Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients Data also demonstrated 64.3% overall response rate w ...

WVE-006: RNA editing for AATD Positive RestorAATion-2 clinical data update Investor presentation September 3, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ...

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age- ...

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lyell’s next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to deliver improved complete response rates and longer duration of responses over currently approved CD19 CAR T-cell therapiesSteering Committee of distinguished lymphoma experts establis ...